Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:rilpivirine
|
| gptkbp:approvalYear |
2011
|
| gptkbp:ATCCode |
J05AG05
|
| gptkbp:CASNumber |
500287-72-9
|
| gptkbp:chemicalFormula |
C22H18N6
|
| gptkbp:contraindication |
severe hepatic impairment
concurrent use with proton pump inhibitors |
| gptkbp:drugClass |
non-nucleoside reverse transcriptase inhibitor
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Edurant
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanismOfAction |
inhibits HIV-1 reverse transcriptase
|
| gptkbp:pregnancyCategory |
B
B1 |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
nausea headache rash insomnia |
| gptkbp:UNII |
N8VZ3C4A6D
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|